SCHEMBL23068622

SCHEMBL23068622

CCNc1nccc(-c2sc(NC(=O)Nc3ccc(CN4CCN(C(C)=O)CC4)c(C(F)(F)F)c3)nc2C)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 7/20 0.54
CDK9 P50750 6/20 0.54
ABL1 P00519 4/20 0.54
AURKA O14965 4/20 0.54
CDK7 P50613 4/20 0.54
AURKB Q96GD4 4/20 0.54
RET P07949 3/20 0.54
NTRK1 P04629 2/20 0.54
NTRK2 Q16620 2/20 0.54
WEE1 P30291 2/20 0.54
ALK Q9UM73 2/20 0.54
KDR P35968 2/20 0.54
MAP4K2 Q12851 2/20 0.54
MAPK14 Q16539 2/20 0.54
CHEK1 O14757 1/20 0.54
DAPK3 O43293 1/20 0.54
JAK2 O60674 1/20 0.54
PRKD3 O94806 1/20 0.54
MAP4K4 O95819 1/20 0.54
PAK4 O96013 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29629236 1.00 CDK8 (0.54) CDK8CDK9ABL1AURKACDK7
SCHEMBL23068654 0.94 RET (0.55) CDK8CDK9ABL1AURKACDK7
SCHEMBL29629256 0.94 RET (0.55) CDK8CDK9ABL1AURKACDK7
SCHEMBL23068639 0.93 EGFR (0.54) CDK8ABL1RETNTRK1NTRK2
SCHEMBL29629211 0.93 EGFR (0.54) CDK8ABL1RETNTRK1NTRK2
SCHEMBL23068652 0.93 CDK9 (0.53) CDK8CDK9ABL1AURKACDK7
SCHEMBL29629215 0.93 CDK9 (0.53) CDK8CDK9ABL1AURKACDK7
SCHEMBL22684882 0.91 ABL1 (0.47) CDK8CDK9ABL1AURKACDK7
SCHEMBL29629233 0.91 ABL1 (0.47) CDK8CDK9ABL1AURKACDK7
SCHEMBL23068679 0.91 CDK8 (0.52) CDK8CDK9ABL1AURKACDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111757881-B 5- (Pyrimidin-4-yl) thiazol-2-yl urea derivatives as therapeutic agents 澳升医药公司 2024-05-07 CN claimed
CN-111757881-B 5- (Pyrimidin-4-yl) thiazol-2-yl urea derivatives as therapeutic agents 澳升医药公司 2024-05-07 CN disclosed
US-20230092876-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-03-23 US disclosed
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents AUCENTRA HOLDINGS PTY LTD (AU) 2022-05-10 US disclosed
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents AUCENTRA HOLDINGS PTY LTD (AU) 2022-05-10 US disclosed
US-20210070746-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-03-11 US disclosed
US-20210070746-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230092876-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS CDK8, CDK18, CDK9 CDK8 1/4885CDK9 3/4885ABL1 268/4885
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents CDK8, CDK18, CDK9 CDK8 1/4885CDK9 3/4885ABL1 268/4885
US-20210070746-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS CDK8, CDK18, CDK9 CDK8 1/4885CDK9 3/4885ABL1 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.